Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies
Open accessAbstract
SUMMARY Adoptive transfer of genetically-modified immune cells holds great promise for cancer immunotherapy. CRISPR knock-in targeting can improve cell therapies, but more high-throughput methods are needed to test which knock-in gene constructs most potently enhance primary cell functions in vivo. We developed a widely adaptable technology to barcode and track targeted integrations of large non-viral DNA templates, and applied it to perform pooled knock-in screens in primary human T cells. Pooled knock-in of dozens of unique barcoded templates into the TCR-locus revealed gene constructs that enhanced fitness in vitro and in vivo. We further developed Pooled Knock-In Sequencing (PoKI-Seq), combining single-cell transcriptome analysis and pooled knock-in screening to measure cell abundance and cell state ex vivo and in vivo. This platform nominated a novel TGFβR2–41BB chimeric receptor that improved solid tumor clearance. Pooled knock-in screening enables parallelized re-writing of endogenous genetic sequences to accelerate discovery of knock-in programs for cell therapies.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
0 of 46 cited sources checked · 0 supported · 0 flagged
- Findingown data
Expected DNA barcodes could be selectively sequenced from cells expressing the corresponding knock-in-encoded protein products.
“We first demonstrated that expected DNA barcodes could be selectively sequenced from cells expressing the corresponding knock-in encoded protein products.”
Quote in the paperSubstantial claim - Findingown data
Sorting cells with successful HDR knock-in that co-expressed GFP or RFP strongly enriched for the appropriate DNA barcode isolated and sequenced from either gDNA or cDNA.
“Sorting cells with successful HDR knock in (based on expression of the NY-ESO-1 TCR) that co-expressed either GFP+ or RFP+ strongly enriched for the appropriate DNA barcode isolated sequenced from either gDNA or cDNA (Figure 1C and Figure S2C–E).”
Quote in the paperSubstantial claim - Findingown data
Primers complementary to template homology arm mismatches did not show the same enrichment for correct barcodes in sorted populations.
“However, as expected, primers complementary to the template homology arm mismatches – which should preferentially amplify non-HDR integrated templates – did not show the same enrichment for correct barcodes in the sorted populations (Figure 2E).”
Quote in the paperSubstantial claim - Findingown data
Template switching varied with the stage of library production at which constructs were pooled.
“Template switching varied based on the stage of library production when constructs were pooled, and we chose to pool all subsequent knock-in construct libraries at the electroporation stage (Figure 1E).”
Quote in the paperSubstantial claim - Findingown data
Relative abundances of knock-in construct barcodes could be tracked over time in an expanding population of T cells cultured in IL-2.
“Finally, we were able to readily track the relative abundances of knock-in construct barcodes over time in an expanding population of T cells cultured in interleukin 2 (IL-2).”
Quote in the paperSubstantial claim
- Findingown data
The platform nominated a novel TGFβR2-41BB chimeric receptor that improved solid tumor clearance.
“This platform nominated a novel TGFβR2–41BB chimeric receptor that improved solid tumor clearance.”
Quote in the paperSubstantial claim - Findingown data
The homology arm mismatch sequencing strategy selectively amplified on-target barcodes using the larger 36-member pooled knock-in library.
“We next directly validated the homology arm mismatch sequencing strategy (Figure 1B) to selectively amplify on-target barcodes using the larger 36-member pooled knock-in library.”
Quote in the paperSubstantial claim - Findingreasoning
PCR primers annealing to the inserted knock-in sequence and to the genomic flanking sequence can selectively amplify successful on-target HDR events.
“PCR primers that anneal to the inserted knock-in sequence and to the genomic flanking sequence can then selectively amplify successful on-target HDR events (Figure S2A).”
Quote in the paperSubstantial claim - Findingown data
Following anti-CD3/CD28 stimulation, constructs encoding various synthetic versions of the Fas receptor were strikingly enriched.
“Following anti-CD3/CD28 stimulation, we observed a striking enrichment of constructs encoding various synthetic versions of the Fas receptor (Figure 3B).”
Quote in the paperSubstantial claim- Rests on an assumption: The in vitro conditions used in the pooled screens mimic aspects of tumor microenvironments.
- Findingown data
Only about 25% of cells showed evidence of multiple integrations in the GFP and RFP duplexed barcoded library.
“Only ~25% of cells showed evidence of multiple integrations (Figure 1D and Figure S2E).”
Quote in the paperSubstantial claim - Findingown data
A short DNA sequence that does not match the target genomic locus can be introduced into one homology arm without greatly reducing knock-in efficiency.
“and a short DNA sequence that does not match the target genomic locus can be introduced into one homology arm without a large reduction in knock-in efficiency (Figure 1B and Figure S2B).”
Quote in the paperSubstantial claim - Findingown data
The authors created a flexible method to label and follow targeted insertions of large non-viral DNA templates in primary human T cells.
“We developed a widely adaptable technology to barcode and track targeted integrations of large non-viral DNA templates, and applied it to perform pooled knock-in screens in primary human T cells.”
Quote in the paperSubstantial claim- Rests on an assumption: The field lacks rapid methods to test and directly compare the functions of large DNA knock-in integrations in human primary cells.
- Findingown data
The percentage of reads with GFP or RFP sequencing barcodes closely corresponded to the percentage of GFP- or RFP-positive cells at the protein level across four human donors.
“As expected, the percentage of reads with the GFP or RFP sequencing barcodes closely corresponded to the percentage of GFP or RFP positive cells observed at the protein level across four human donors (Figure 2D).”
Quote in the paperSubstantial claim - Findingown data
A unique barcode for each insert placed within degenerate bases of the TCR-α sequence enabled rapid PCR-based DNA sequencing to measure the abundance of each on-target insert in the pooled population from genomic DNA or reverse-transcribed mRNA.
“Addition of a barcode unique for each insert within degenerate bases of the TCR-α sequence enabled a rapid DNA sequence readout by PCR of the abundance of each individual on-target insert in the pooled population by either of two complementary methods: 1) sequencing directly from genomic DNA (gDNA), or 2) sequencing from reverse transcribed mRNA (cDNA) (Figure 1B).”
Quote in the paperSubstantial claim - Findingown data
For both gDNA and cDNA sequencing, when GFP+ or RFP+ cells were sorted from cells with successful on-target knock-in, the correct barcodes were selectively sequenced using primers that bound the genomic sequence at the rate predicted when accounting for multiple integrations and template switching.
“For both gDNA and cDNA sequencing conditions, when GFP+ or RFP+ cells were sorted from the cells with successful on-target knock-in (NY-ESO-1 TCR+), the correct barcodes were selectively sequenced when using primers that bound the genomic sequence at the rate predicted when taking multiple integrations and template switching into account (Figure 2E and STAR Methods).”
Quote in the paperSubstantial claim - Findingown data
With pooling at the electroporation stage, only about 10% of cells showed evidence of template switching.
“With this pooling strategy only ~10% of cells showed evidence of template switching (e.g. nine in ten knock-in positive cells will have the correct combination of knock-in construct and barcode) (Figure 1E and Figure S2C–J).”
Quote in the paperSubstantial claim - Findingreasoning
The authors developed a deep sequencing strategy that selectively captures on-target knock-in constructs while avoiding NHEJ-edited or unedited target genomic sequences, non-integrated HDR templates, or off-target integrations.
“We developed a deep sequencing strategy that selectively captures on-target knock-in constructs while avoiding NHEJ-edited or un-edited target genomic sequences, non-integrated HDR templates, or off-target integrations (Figure 1B and Figure S2A).”
Quote in the paperSubstantial claim - Findingown data
All knock-in constructs in the 36-member library were well-represented across multiple pooled knock-in experiments in four independent human donors.
“Quantitative barcode sequencing demonstrated that even with the larger library all knock-in constructs were well-represented across multiple pooled knock-in experiments performed in four independent human donors (Figure 2A).”
Quote in the paperSubstantial claim - Findingown data
Pooled knock-in of many unique barcoded templates into the TCR locus revealed gene constructs that improved T cell fitness in vitro and in vivo.
“Pooled knock-in of dozens of unique barcoded templates into the TCR-locus revealed gene constructs that enhanced fitness in vitro and in vivo.”
Quote in the paperSubstantial claim - Findingown data
PoKI-Seq combines single-cell transcriptome analysis with pooled knock-in screening to measure cell abundance and cell state ex vivo and in vivo.
“We further developed Pooled Knock-In Sequencing (PoKI-Seq), combining single-cell transcriptome analysis and pooled knock-in screening to measure cell abundance and cell state ex vivo and in vivo.”
Quote in the paperSubstantial claim- Rests on an assumption: Cell abundance alone is insufficient to assess cellular function, and an ideal screening method should also assess modified cell states.
- Findingown data
About 90% of barcodes from sorted GFP+ cells were correct.
“~ 90% of barcodes from sorted GFP+ cells were correct (Figure S2J).”
Quote in the paperSubstantial claim - Findingown data
A larger library of 36 pooled templates could be introduced and tracked by their DNA barcodes.
“Quantitative barcode sequencing demonstrated that even with the larger library all knock-in constructs were well-represented across multiple pooled knock-in experiments performed in four independent human donors (Figure 2A).”
Quote in the paperSubstantial claim - Findingown data
A truncated CTLA4 construct showed reduced cell killing, consistent with its impaired fitness in the pooled knock-in screens.
“In contrast, a truncated CTLA4 construct showed reduced cell killing (Figure 4D–E), consistent with its impaired fitness in the pooled knock-in screens (although diminished proliferation assessed by CFSE was not observed with this individual construct, Figure S5B).”
Quote in the paperNot a substantial claim - Findingown data
Sorting GFP+ or RFP+ cells from the pooled knock-in positive population strongly enriched for the expected template barcodes, confirming PoKI-Seq can accurately assign specific knock-in constructs to cells.
“Sorting GFP+ or RFP+ cells from the pooled knock-in positive population (NY-ESO-1 TCR+) strongly enriched for the expected template barcodes, confirming the ability of PoKI-Seq to accurately assign specific knock-in constructs to cells (Figure 5B).”
Quote in the paperSubstantial claim - Findingown data
With exogenous TGFβ, chimeric receptors derived from TGFβR2 maintained expression of the proliferation genes MKI67 and TOP2A, whereas TGFβ suppressed these genes in cells carrying other knock-in constructs.
“For example, in the presence of exogenous TGFβ, TGFβR2-derived chimeric receptors promoted continued expression of various hallmark proliferative genes such as MKI67 and TOP2A, while these genes were inhibited by TGFβ in cells expressing other KI constructs.”
Quote in the paperSubstantial claim - Findingown data
Distinct clusters of cell states emerged in PoKI-Seq of cells from two human blood donors following ex vivo stimulation with or without exogenous TGFβ, especially with TGFβ.
“Distinct clusters of cell states emerged, especially with addition of exogenous TGFβ (Figure 5D–E).”
Quote in the paperNot a substantial claim - Findingown data
Density plots revealed significant cell state differences in T cells modified with TGFβR2-derived constructs compared to control and non-TGFBR2-derived constructs in the stimulation plus TGFβ culture condition.
“Density plots for individual knock-in constructs revealed significant cell state differences in T cells modified with TGFβR2-derived constructs compared to control and non-TGFBR2-derived constructs in the stimulation plus TGFβ culture condition (Figure 5G).”
Quote in the paperSubstantial claim - Findingown data
The TGFβR2-41BB construct increased target in vitro cancer cell killing in T cells from four human blood donors across a range of effector to target cell ratios.
“Although this was not the phenotype initially tested in the pooled screens, the TGFβR2–41BB increased target in vitro cancer cell killing in T cells from four human blood donors across a range of effector to target cell ratios (Figure 4D–E).”
Quote in the paperSubstantial claim - Findingreasoning
A truncated CTLA4 protein decreased T cell fitness in the same conditions across four donors.
“In contrast, a truncated CTLA4 protein decreased T cell fitness in the same conditions across four donors”
Quote in the paperNot a substantial claim - Findingown data
The pooled knock-in screens confirmed the functional effects of a recently described truncated Fas receptor included as a positive control.
“The pooled knock-in screens confirmed the functional effects of a recently described truncated Fas receptor (Yamamoto et al., 2019) included as a positive control”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Yamamoto et al., 2019 source
Not checked in the free run.
- Findingown data
The screens identified novel synthetic Fas switch receptors, including one with a 4-1BB intracellular domain, that promoted T cell fitness in stimulated conditions.
“also identified novel synthetic Fas switch receptors, including one with a 4–1BB intracellular domain, that also promoted T cell fitness in stimulated conditions (Figure 3B).”
Quote in the paperSubstantial claim - Findingown data
In the presence of exogenous TGFβ, the TGFβR2-41BB construct rescued impaired cancer cell killing across experiments from four healthy human donors.
“In the presence of exogenous TGFβ, the TGFβR2–41BB construct successfully rescued the impaired cancer cell killing across experiments performed from four healthy human donors (Figure 4F).”
Quote in the paperSubstantial claim - Findingown data
The overall proportion of cells assigned two knock-in constructs closely corresponded with predicted frequencies based on GFP/RFP 2-member library experiments.
“The overall proportion of cells assigned two knock-in constructs (Figure 5C) closely corresponded with predicted frequencies based on GFP/RFP 2-member library experiments (Figure 1D).”
Quote in the paperSubstantial claim - Findingown data
Addition of TGFβ1 gave cells expressing engineered TGFβR receptors a selective fitness advantage, including a previously described truncated TGFβR2 receptor and a novel chimeric TGFβR2-41BB receptor.
“Finally, addition of the immunosuppressive cytokine TGFβ1 gave cells expressing engineered TGFβR receptors a selective fitness advantage, including both a previously described truncated TGFβR2 receptor (Gorelik and Flavell, 2000; Kim et al., 2017; Kloss et al., 2018) included as a positive control and a novel chimeric TGFβR2–41BB receptor (Figure 3D and Figure S4D–E).”
Quote in the paperSubstantial claim0 of 3 sources checked - Findingown data
Cells possessing TGFβR2-derived constructs were more likely to be found in clusters otherwise associated with the stimulation-only condition rather than the stimulation + TGFβ condition, including cluster 8 (proliferation) and cluster 12 (cell killing).
“Specifically, cells possessing TGFβR2-derived constructs were more likely to be found in clusters otherwise associated with the stimulation-only condition rather than the stimulation + TGFβ condition, including cluster 8, characterized by genes associated with cell proliferation, and cluster 12, characterized by genes associated with cell killing (Figures 5E, H and S6E–F).”
Quote in the paperSubstantial claim - Findingreasoning
In vivo screens had greater variance between replicates and donors than in vitro screens.
“Due to the lower number of human T cells isolatable from individual solid tumor xenografts (generally 10,000–20,000 cells per mouse), greater variance between replicates and donors was observed in the in vivo screens than in the in vitro screens (Figure S7B–C).”
Quote in the paperNot a substantial claim - Findingown data
Single-cell template barcode assignments were confirmed further as transcripts encoded by corresponding knock-in constructs tended to be expressed at increased levels.
“Single cell template barcode assignments were confirmed further as transcripts encoded by corresponding knock-in constructs tended to be expressed at increased levels, similar to what had been observed at the protein level with delivery of individual knock-in constructs (Figure 4B and Figure S6D).”
Quote in the paperSubstantial claim - Findingreasoning
The TCF7 cell population did not improve tumor control relative to tNGFR controls.
“Consistent with TCF7 promoting TIL abundance, but not promoting mature effector cytokine expressing cells, the TCF7 cell population did not enhance tumor control relative to tNGFR controls (Figure 7B).”
Quote in the paperSubstantial claim - Findingown data
When sorted GFP or RFP positive cells were assigned two knock-in constructs, at least one of the assigned constructs was almost always either GFP or RFP respectively.
“As expected, when sorted GFP or RFP positive cells were assigned two knock-in constructs, at least one of the knock-in constructs assigned was almost always either GFP or RFP respectively (Figure 5C).”
Quote in the paperSubstantial claim - Findingown data
Each knock-in construct caused distinct enrichment patterns in individual cell clusters in both TCR stimulation and stimulation plus TGFβ conditions that broadly corresponded to results from the in vitro pooled knock-in screens.
“Each knock-in construct caused distinct enrichment patterns in individual cell clusters in both TCR stimulation and stimulation plus TGFβ conditions that broadly corresponded to results from the in vitro pooled knock-in screens (Figure S6E).”
Quote in the paperSubstantial claim - Findingown data
TGFβR2-derived knock-in constructs were relatively depleted from cells in clusters otherwise promoted by TGFβ treatment (Clusters 2, 4 and 6).
“Similarly, the TGFβR2-derived knock-in constructs were relatively depleted from cells in the clusters otherwise promoted by TGFβ treatment (Clusters 2, 4 and 6) (Figure 5H).”
Quote in the paperSubstantial claim - Findingown data
The TGFβR2-41BB construct markedly reduced tumor sizes compared with TCR+tNGFR (P < 0.0001 at day 33).
“In contrast, the TGFβR2–41BB receptor construct that promoted abundance and effector cytokine gene expression in TILs markedly reduced tumor sizes (P < 0.0001 at day 33 vs TCR+tNGFR).”
Quote in the paperSubstantial claim - Findingown data
The TCF7 knock-in construct, which had only mild and non-significant effects in vitro, increased T cell accumulation in the tumor microenvironment across four donors.
“The TCF7 knock-in construct that only showed mild effects in vitro (not reaching statistical significance) promoted accumulation of T cells in the tumor microenviroment across four donors (Figure 6B).”
Quote in the paperSubstantial claim - Findingown data
TCR stimulation without anti-CD28 co-stimulation selected for various chimeric receptors with intracellular CD28 domains such as TIM3-CD28 and CTLA4-CD28.
“TCR stimulation without anti-CD28 co-stimulation selected for various chimeric receptors with intracellular CD28 domains such as TIM3-CD28 and CTLA4-CD28 (Figure S4C).”
Quote in the paperSubstantial claim - Findingown data
Exposure to TGFβ caused the largest transcriptional changes among the conditions tested.
“Hierarchical clustering revealed that exposure to TGFβ drove the greatest transcriptional changes (Figure 5I and Figure S6G).”
Quote in the paperNot a substantial claim - Findingown data
The lead construct showed markedly enhanced clearance of an in vivo solid tumor model.
“This lead construct indeed showed markedly enhanced clearance of an in vivo solid tumor model.”
Quote in the paperSubstantial claim - Findingown data
Increased cell expansion induced by the TGFβR2-41BB construct correlated with evidence of increased cell proliferation in the presence of TGFβ, measured by CFSE dilution relative to control cells.
“Increased cell expansion induced by the TGFβR2–41BB construct correlated with evidence of increased cell proliferation in the presence of TGFβ (measured by CFSE dilution relative to control cells) (Figure 4C and Figure S5B).”
Quote in the paperSubstantial claim - Findingown data
The measured template-switching rate for the pooled electroporation condition used in the study was about 10%.
“the rate of template switching in the pooled electroporation condition used throughout the study was determined to be ~10% (Figure 1E)”
Quote in the paperSubstantial claim - Findingown data
The estimated rate of biallelic knock-in was about 25% among cells positive for knock-in.
“Biallelic knock-in rate was estimated to be ~25% of total knock-in positive cells (Figure 1D and Figure S2E)”
Quote in the paperSubstantial claim - Interpretationown data
Engineered cell phenotypes could be quantitatively tracked in pooled knock-in experiments through DNA barcode sequencing.
“These results showed that engineered cell phenotypes could be quantitatively tracked in pooled knock-in experiments through DNA barcode sequencing.”
Quote in the paperSubstantial claim - Premisecitation
Pooled screening approaches have been challenged by template switching that complicates interpretation of DNA barcode readouts.
“Pooled screening approaches have been challenged by template switching that complicate interpretation of DNA barcode readouts (Hanna and Doench, 2018; Hegde et al., 2018; Sack et al., 2016).”
Quote in the paperSubstantial claim0 of 3 sources checked - Premisecitation
Most homology arm sequences of an HDR template are not incorporated into on-target HDR integrations.
“Briefly, the majority of a HDR template’s homology arm sequences are not incorporated with on-target HDR integrations (Paquet et al., 2016)”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Paquet et al., 2016 source
Not checked in the free run.
- Premisecitation
Targeted integration of antigen receptor genes into defined genomic loci has potential advantages.
“More recent work has revealed potential advantages of targeted integrations of antigen receptor genes into defined genomic loci (Eyquem et al., 2017), which can be achieved with programmable nucleases such as CRISPR-Cas9 along with viral or non-viral knock-in templates (Gwiazda et al., 2016; Eyquem et al., 2017; Roth et al., 2018).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Eyquem et al., 2017 source
Not checked in the free run.
- Premisecitation
Multiple barcoded templates introduced into the same cell could complicate interpretation of each one's effects.
“In addition, multiple barcoded templates introduced in the same cell could complicate interpretation of each one’s effects (Feldman et al., 2018; Roth et al., 2018).”
Quote in the paperSubstantial claim0 of 2 sources checked- cites Feldman et al., 2018
Not checked in the free run.
- cites Roth et al., 2018 source
Not checked in the free run.
- Premisecitation
Excessive antigen density and kinetics of antigen exposure in solid tumors can drive T cell exhaustion or dysfunction.
“The excessive antigen density and kinetics of antigen exposure in solid tumors can drive exhaustion or dysfunction of T cells (Khan et al., 2019; Wherry, 2011).”
Quote in the paperSubstantial claim0 of 2 sources checked - Premisecitation
Suppressive cytokines such as TGFβ can be co-opted by tumors to inhibit T cell function.
“Suppressive cytokines such as TGFβ can be co-opted by tumors to inhibit T cell function (Dahmani and Delisle, 2018; Thomas and Massagué, 2005).”
Quote in the paperSubstantial claim0 of 2 sources checked- cites Dahmani and Delisle, 2018
Not checked in the free run.
- cites Thomas and Massagué, 2005 source
Not checked in the free run.
- Premisecitation
Tregs, MDSCs, and dendritic and stromal cell populations within the tumor can deprive T cells of necessary co-stimulatory signals or induce inhibitory signals.
“Tregs, myeloid derived suppressor cells (MDSCs), and dendritic and stromal cell populations within the tumor can deprive T cells of necessary co-stimulatory signals or induce inhibitory signals (Chen and Mellman, 2013; Ostrand-Rosenberg et al., 2012).”
Quote in the paperSubstantial claim0 of 2 sources checked - Interpretationcitation
Next-generation cellular immunotherapies will likely need enhanced function to overcome solid tumor challenges.
“Next-generation cellular immunotherapies will likely need to be engineered with enhanced function to overcome these challenges presented by solid tumors (Rafiq et al., 2019).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Rafiq et al., 2019
Not checked in the free run.
- Rests on an assumption: CAR T cells have not proved effective for solid tumors.
- Interpretationnone given
The translational potential for knock-in of large gene cassettes to rewrite cell programs is greater than that of gene ablation.
“While gene ablation can enhance cell therapies, the translational potential for knock-in of large gene cassettes to re-write cell programs is even greater.”
Quote in the paperNot a substantial claim - Premisecitation
Coupling pooled CRISPR gene knockouts with single-cell RNA sequencing provides a powerful approach to assess the effect of each gene perturbation on cell state.
“Coupling pooled CRISPR gene knockouts with single cell RNA sequencing provides a powerful approach to assess the effect of each gene perturbation on cell state (Adamson et al., 2016; Datlinger et al., 2017; Dixit et al., 2016; Jaitin et al., 2016).”
Quote in the paperNot a substantial claim0 of 3 sources checked - Interpretationown data
Pooled knock-in screening allows parallel rewriting of endogenous genetic sequences to speed discovery of knock-in programs for cell therapies.
“Pooled knock-in screening enables parallelized re-writing of endogenous genetic sequences to accelerate discovery of knock-in programs for cell therapies.”
Quote in the paperSubstantial claim - Interpretationreasoning
Barcoded pools of non-viral HDR templates can now be used to explore in vitro and in vivo functions of diverse sequence variants at targeted coding and non-coding elements in primary human cell genomes.
“Barcoded pools of non-viral HDR templates can now be used to explore the in vitro and in vivo functions of diverse sequence variants at targeted coding and non-coding elements in the genomes of primary human cells.”
Quote in the paperSubstantial claim - Interpretationown data
Pooled knock-in screening combined with scRNA-seq can rapidly identify new DNA sequences with potential to improve therapeutic T cell functions.
“Taken together, pooled knock-in screening combined with scRNA-seq can rapidly reveal new DNA sequences with potential to enhance therapeutic T cell functions.”
Quote in the paperSubstantial claim - Interpretationreasoning
Effective barcoding of targeted knock-in sequences allowed single-cell transcriptome readouts in a pool of modified cells to assess each construct's effect on cell state, a method termed PoKI-seq.
“Effective barcoding of targeted knock-in sequences also allowed single-cell transcriptome readouts in a pool of modified cells to assess the effects of each knock-in construct on cell state, a method we term Pooled Knock-In Sequencing (PoKI-seq).”
Quote in the paperSubstantial claim - Interpretationown data
Pooled knock-in screens highlight condition-specific functional enhancements conferred by synthetic proteins or forced expression of key regulators.
“These data from pooled knock-in screens highlight condition-specific functional enhancements conferred by synthetic proteins or forced expression of key regulators.”
Quote in the paperSubstantial claim - Interpretationreasoning
Targeted non-viral pooled knock-in screens have notable advantages over other systems that could be used to discover effects of gene gain-of-function.
“Targeted non-viral pooled knock-in screens have notable advantages over other systems that potentially could be used to discover effects of gene gain-of-function.”
Quote in the paperSubstantial claim- Rests on an assumption: Technical challenges have limited CRISPRa applications in therapeutically relevant primary human cell types.
- Rests on an assumption: CRISPRa can only induce natural gene products encoded in the genome and does so with variable efficiency.
- Rests on an assumption: A major challenge to quantitative tracking of targeted genomic integrations of pooled knock-in constructs has been the abundance of non-integrated DNA templates in targeted cells and the risk of template switching during molecular steps of pooled library production, integration, and sequencing.
- Rests on an assumption: Most over-expression studies have been performed with lentiviral or retroviral vectors.
- Interpretationown data
The pooled screens, although focused on cell-intrinsic effects on T cell fitness, also identified novel gene constructs that can enhance in vitro anti-cancer cell efficacy.
“Although the pooled screens focused on cell-intrinsic effects on T cell fitness, they also successfully identified novel gene constructs that can enhance in vitro anti-cancer cell efficacy.”
Quote in the paperSubstantial claim - Interpretationreasoning
The paper overcame technical limitations in tracking targeted genomic integrations with a widely adaptable technology to barcode and track on-target integrations of HDR templates in a pooled library.
“Here we overcame these technical limitations with a widely adaptable technology to barcode and track on-target integrations of HDR templates in a pooled library.”
Quote in the paperSubstantial claim- Rests on an assumption: A major challenge to quantitative tracking of targeted genomic integrations of pooled knock-in constructs has been the abundance of non-integrated DNA templates in targeted cells and the risk of template switching during molecular steps of pooled library production, integration, and sequencing.
- Study design and conductown data
The results of the pooled targeted knock-in screens were reproducible across multiple biological replicates, technical replicates, sorting conditions and pooling conditions.
“The results of these pooled targeted knock-in screens were reproducible across multiple biological replicates, technical replicates, sorting conditions and pooling conditions (Figure S4F–H).”
Quote in the paperSubstantial claim - Interpretationreasoning
Each knock-in construct can be tracked in the targeted cell population under diverse in vitro and in vivo conditions to reveal the most effective modifications.
“Each knock-in construct can be tracked in the targeted cell population under diverse in vitro and in vivo conditions to reveal the most effective modifications.”
Quote in the paperSubstantial claim - Premisecitation
TCF7 expression is lost when cells differentiate into effector cells.
“but TCF7 expression was lost upon differentiation into effector cells (Siddiqui et al., 2019).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Siddiqui et al., 2019 source
Not checked in the free run.
- Interpretationown data
PoKI-Seq can reveal target gene pathways and context-dependent cell-state changes caused by individual knock-in constructs.
“More generally PoKI-Seq was able to reveal target gene pathways and context-dependent changes in cell state modulated by individual knock-in constructs.”
Quote in the paperSubstantial claim - Interpretationreasoning
The pooled knock-in platform offers a new opportunity to systematically screen large gene constructs that can be added to T cells to modulate critical functions for effective cell therapies.
“The pooled knock-in platform presented here offers a new opportunity to screen systematically for large gene constructs that can be added to a T cell to modulate critical functions for effective cell therapies.”
Quote in the paperSubstantial claim- Rests on an assumption: The field needs a systematic approach to compare complex transgene constructs head-to-head and determine which are most effective for specific disease indications.
- Interpretationown data
PoKI-Seq can phenotype individual cells with either single or multiple knock-in constructs.
“Overall, these experiments confirmed the molecular biology of PoKI-seq and also demonstrated its ability to phenotype individual cells with either single or multiple knock-in constructs.”
Quote in the paperSubstantial claim - Interpretationreasoning
Non-viral pooled knock-in screening will accelerate discovery and development of synthetic DNA sequences to reprogram specificity and function of adoptive cellular therapies.
“Non-viral pooled knock-in screening will accelerate the discovery and development of synthetic DNA sequences to reprogram the specificity and function of adoptive cellular therapies.”
Quote in the paperNot a substantial claim- Rests on an assumption: The field needs a systematic approach to compare complex transgene constructs head-to-head and determine which are most effective for specific disease indications.
- Interpretationown data
The pooled library-based approach can identify individual knock-in sequences to engineer T cell function.
“These findings validated the pooled library-based approach to identify individual knock-in sequences to engineer T cell function.”
Quote in the paperSubstantial claim - Interpretationown data
PoKI-seq offers a complementary single-cell approach to study large knock-in perturbations in pooled experiments.
“PoKI-seq offers a complementary single-cell approach to study large knock-in perturbations in pooled experiments.”
Quote in the paperSubstantial claim - Interpretationreasoning
Knock-in of large genetic constructs enables engineering synthetic receptors that re-wire the signal T cells receive upon TGFβ exposure in the tumor microenvironment, including switching suppressive TGFβ signaling to stimulatory 41BB signaling.
“Knock-in of large genetic constructs enables the engineering of synthetic receptors to re-wire the signal T cells receive when exposed to TGFβ in the tumor microenvironment, including switching the suppressive TGFβ signal to a stimulatory 41BB signal.”
Quote in the paperSubstantial claim - Interpretationown data
PoKI-Seq confirmed that multiple TGFβR2-derived receptors share biological effects, converting a suppressive signal into one that promotes proliferation and an effector cell state.
“PoKI-Seq confirmed the shared biological effects of multiple TGFβR2-derived receptors, which convert a suppressive signal into a signal that promotes cell proliferation and an effector cell state.”
Quote in the paperSubstantial claim - Interpretationreasoning
These sources of variability could complicate interpretation of pooled screens by introducing false positives and false negatives.
“These sources of variability could complicate interpretation of pooled screens, introducing both false positives and false negatives.”
Quote in the paperSubstantial claim - Interpretationreasoning
The decreased fitness from truncated CTLA4 was likely due to competition for CD28 co-stimulatory signaling.
“likely due to competition for CD28 co-stimulatory signaling (Figure 3B).”
Quote in the paperNot a substantial claim - Interpretationown data
The preclinical success of a novel construct nominated by pooled knock-in screens highlights the power of the platform.
“The preclinical success of a novel construct nominated by pooled knock-in screens highlights the power of the platform.”
Quote in the paperSubstantial claim - Interpretationown data
Complementary in vitro and in vivo assays are powerful for assessing synthetic gene functions.
“These results underscore the power of complementary in vitro and in vivo assays to assess synthetic gene functions.”
Quote in the paperSubstantial claim - Interpretationown data
The metrics established the fidelity of barcode assignment to single cell transcriptomes for the PoKI-Seq platform.
“These metrics together established the fidelity of barcode assignment to single cell transcriptomes for the PoKI-Seq platform.”
Quote in the paperSubstantial claim - Interpretationreasoning
For a two-member library, the actual switching rate Y is given by Y = 2/(1/X - 1), where X is the observed rate.
“Simplifying the equation yields: 3)Y/X=2+2*X+2*X2+2*X3+…+2*Xn 4)Y/X=2+Y 5)(Y/X)−Y=2 6)Y*(1/X−1)=2 7)Y=2/(1/X−1)”
Quote in the paperSubstantial claim- The authors state this as an assumption: Template switching is random, and any barcode that is swapped is equally likely to switch to any other barcode.
- The authors state this as an assumption: A template that has switched once is equally likely to switch again.
- Interpretationreasoning
Prior to template switching, 1000 of 1250 alleles are expected to contain the correct construct or barcode.
“Therefore, out of 1250 total alleles, 1000 would be predicted to contain the correct knock-in construct/barcode before accounting for template switching.”
Quote in the paperSubstantial claim- The authors state this as an assumption: The knock-in library is arbitrarily large.
- Interpretationreasoning
In an arbitrarily large library, switching to templates with the same barcode becomes negligible, so observed and actual template switching rates converge.
“In a library of arbitrarily large size, there will be no significant switching with templates containing the same barcode, and thus the observed and actual amounts of template switching will converge.”
Quote in the paperSubstantial claim - Interpretationreasoning
Overall, 900 of 1250 alleles, or 72%, are predicted to contain the correct knock-in barcode.
“In total then, 900 out of 1250 alleles, or 72% of alleles, will contain the correct knock-in barcode.”
Quote in the paperNot a substantial claim - Interpretationnone given
In biallelic knock-in cells, half of the alleles are expected to carry a different knock-in construct or barcode than the sorted construct, assuming an arbitrarily large library.
“Half of the alleles in biallelic knock-in cells will have a different knock-in construct/barcode than the sorted (GFP) knock-in construct/barcode, assuming an arbitrarily large knock-in library.”
Quote in the paperSubstantial claim- The authors state this as an assumption: The knock-in library is arbitrarily large.
- Interpretationreasoning
At a 10% switching rate, 100 of the 1000 correct-construct alleles are expected to have a different barcode.
“Assuming a 10% rate of template switching, 100 out of 1000 alleles with the correct knock-in construct (GFP) will contain a barcode for a different construct.”
Quote in the paperSubstantial claim
- May combine two claims. 36
- Classified as probably not a substantial claim. 13
May combine two claims.
Findingown dataThe library contained large knock-in constructs ranging from 2 kb to 3 kb, and even the largest constructs were well-represented across biological replicates.
“The library contained large knock-in constructs ranging from 2 kb to 3 kb and even the largest constructs were well-represented across these biological replicates (Figure 2B).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataBarcode abundance was maintained throughout expansion for all constructs, except the IL2RA-encoding construct enriched over time.
“Barcode abundance was maintained throughout expansion for all constructs, with a notable exception of the knock-in construct encoding IL2RA, the high affinity receptor for the interleukin (IL-2), which enriched over time in culture consistent with its known roles promoting T cell fitness (Figure 2F–G).”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataTGFβR2-41BB induced a transcriptional program distinct from TCF7, with higher expression of effector cytokines such as IFN-ɣ.
“the TGFβR2–41BB knock-in induced a distinct transcriptional program compared to TCF7 knock-in cells, with higher expression of effector cytokines such as IFN-ɣ that could enhance tumor clearance.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataBoth TCF7 and TGFβR2-41BB increased expression of TNFSFR9 (4-1BB) relative to control cells.
“While both TCF7 and TGFβR2–41BB promoted expression of genes such as TNFSFR9 (4–1BB) relative to control cells”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim.
Findingnone givenBarcodes could be sequenced from either cDNA or genomic DNA.
“Barcodes could be sequenced from either cDNA or genomic DNA”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataWith excessive stimulation, TCF7 slightly increased cell abundance, but this effect did not reach statistical significance.
“With excessive stimulation, which partially mirrors antigenic abundance in tumor environments, the transcription factor TCF7 (encoding the protein TCF1) slightly increased cell abundance, although this effect did not reach statistical significance (Figure S4B).”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataCells with TGFβR2-41BB were the only ones that cleared the solid tumor model at the tested doses, and this was reproducible in many mice from four human blood donors.
“Cells with the TGFβR2–41BB construct were the only ones that successfully cleared the solid tumor model at the doses tested here, an effect that was reproducible in many of the mice tested with modified T cells from 4 human blood donors (Figure 7B–C).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataThe anti-apoptotic FAS-41BB chimera and anti-suppressive TGFβR2-41BB chimera both promoted context-dependent increased expansion relative to controls.
“Indeed, the anti-apoptotic FAS-41BB chimera and anti-suppressive TGFβR2–41BB chimera both promoted context-dependent increased expansion relative to controls (Figure 4C and Figure S5B).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataClustering of knock-in constructs across all genes differentially expressed in the identified single cell clusters showed strong similarity between the TGFβR2-derived constructs in the presence of TGFβ and revealed downstream target genes modulated by the receptors.
“Clustering of knock-in constructs across all genes differentially expressed in the identified single cell clusters showed strong similarity between the TGFβR2-derived constructs in the presence of TGFβ and revealed downstream target genes that are modulated by the receptors.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataTCF7 was relatively enriched in CCR7+ tumor-infiltrating lymphocytes, whereas TGFβR2-41BB was relatively enriched in IL-2+ and IFNG+ TIL populations.
“Strikingly, the TCF7 construct was relatively enriched in CCR7+ TILs, while TGFβR2–41BB was relatively enriched in both IL-2+ and IFNG+ TIL populations (Figure 6D).”
Quote in the paperSubstantial claimMay combine two claims.
FindingcitationDroplet doublets could appear as multiple barcode calls, but the predicted doublet rate of about 2% would account for only a fraction of cells with more than one barcode.
“Droplet doublets could also appear as multiple barcode calls, but the predicted doublet rate of ~2% (Zheng et al., 2017) would account for only a fraction of the cells with more than one barcode.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Zheng et al., 2017 source
Not checked in the free run.
May combine two claims.
Findingown dataSingle-cell transcriptomes showed high overlap between cells from two human donors and marked differences between ex vivo expanded input T cells and tumor-infiltrating T cells, including differential expression of proliferation- or effector-function genes.
“A UMAP representation of the single cell transcriptomes showed a high degree of overlap between cells from two human donors and marked differences between the ex vivo (input) cell population and tumor infiltrating (in vivo) T cells including differential expression of genes associated with proliferation or effector function (Figure 6C).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataOver 40,000 individual cells were sequenced, of which about 58% were successfully assigned one or two barcodes.
“Over 40,000 individual cells were sequenced, of which ~58% were successfully assigned one (monoallelic) or two (biallelic) barcodes (Figure 5F).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataT cells engineered with a polycistronic NY-ESO-1 TCR construct plus control tNGFR, TCF7, or TGFβR2-41BB all significantly reduced tumor size compared with vehicle injections.
“T cells engineered with a polycistronic knock-in construct expressing a NY-ESO-1 specific TCR (1G4 clone) along with either a control construct (tNGFR), the transcription factor TCF7, or the chimeric TGFβR2–41BB receptor all showed statistically significant reductions in tumor size relative to vehicle only injections of media (Figure 7B).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataBoth TCF7 and TGFβR2-derived synthetic receptors increased T cell abundance in solid tumors but induced different cell states.
“While both the transcription factor TCF7 and TGFβR2-derived synthetic receptors increased T cell abundance in solid tumors, they induced different cell states.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataThe integrated pooled knock-in platform nominated a lead hit, TGFβR2-41BB, that increased T cell fitness in vivo and promoted key effector cytokines including IFNɣ.
“Our integrated pooled knock-in platform nominated a lead hit (TGFβR2–41BB) that increased T cell fitness in vivo and promoted key effector cytokines including IFNɣ.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataSurface and intracellular staining of cells with eight individual knock-in constructs revealed robust expression for each expected protein, including increased expression of Fas and CD25 (IL2RA) above endogenous levels in stimulated T cells.
“Surface and intracellular staining of cells with eight individual knock-in constructs revealed robust expression for each expected protein, including increased expression of Fas and CD25 (IL2RA) above endogenous expression levels in stimulated T cells (Figure 4B and Figure S5A).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataAcross four human donors, several knock-in constructs caused statistically significant accumulation of engineered T cells in the tumor environment in vivo, including one construct not found in vitro.
“Nonetheless, across four individual human donors, several knock-in constructs promoted statistically significant in vivo accumulation of engineered T cells in the tumor environment (Figure 6B), including a construct not identified in the in vitro screens.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationNext-generation T cell therapies are being engineered with transgenes designed to overcome suppressive signals in the tumor environment.
“Next-generation T cell therapies are being engineered with transgenes designed to overcome suppressive signals in the tumor environment (Kloss et al., 2018; Lynn et al., 2019; Yamamoto et al., 2019).”
Quote in the paperNot a substantial claim0 of 3 sources checkedProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationAntigen-specific human T cells can be produced ex vivo by non-targeted viral transduction of defined TCRs, CARs, or other synthetic receptors.
“Antigen-specific human T cells can be generated ex vivo by non-targeted viral transduction of defined T cell receptors (TCRs), chimeric antigen receptors (CARs), or other synthetic receptors (Esensten et al., 2017).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Esensten et al., 2017 source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationFas is a TNF super family surface receptor that mediates apoptosis through interactions with its ligand, FASL.
“Fas is a TNF super family surface receptor that mediates apoptosis through interactions with its ligand, FASL (Strasser et al., 2009).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Strasser et al., 2009 source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationCRISPR-Cas9 ablation of checkpoint targets such as PD-1 in adoptive T cell therapies has shown increased functionality in certain models and is being pursued clinically.
“CRISPR-Cas9 genetic ablation of checkpoint targets such as PD-1 in adoptive T cell therapies has also shown increased functionality in certain models and is being persued clinically (Ren et al., 2017; Rupp et al., 2017; Stadtmauer et al., 2020; Su et al., 2016).”
Quote in the paperNot a substantial claim0 of 3 sources checkedMay combine two claims.
PremisecitationGenome-scale pooled CRISPR loss-of-function screens allow forward genetic studies in many mammalian cell types, including primary T cells, where they have identified genes that may be targeted in future immunotherapies.
“Genome-scale pooled CRISPR loss-of-function screens now allow forward genetic studies in many mammalian cell types (Wang et al., 2014; Shalem et al., 2014) including primary T cells where they have identified genes that may be targeted in future immunotherapies (Dong et al., 2019; Shifrut et al., 2018; Wei et al., 2019).”
Quote in the paperNot a substantial claim0 of 3 sources checkedMay combine two claims.
Interpretationown dataLarge pooled knock-in libraries can be generated and their barcodes quantitatively sequenced in a human T cell population.
“These results showed large pooled knock-in libraries can be generated and their barcodes can be quantitatively sequenced in a human T cell population.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationGenetically engineered immune cell therapies are effective for some cancer types but still cannot cure most tumors.
“Genetically engineered immune cell therapies have proven effective for treatment of some cancer types (Esensten et al., 2017; Fesnak et al., 2016; June and Sadelain, 2018; Sadelain et al., 2017), but they still cannot cure most tumors.”
Quote in the paperSubstantial claim0 of 3 sources checkedMay combine two claims.
Interpretationown dataThe data suggest TCF7 promotes a more naïve or quiescent state, while TGFβR2-41BB promotes accumulation of cells expressing key effector cytokine genes.
“These data suggest that TCF7 promotes a more naïve or quiescent state, whereas the TGFβR2–41BB construct promotes accumulation of cells expressing key effector cytokine genes.”
Quote in the paperSubstantial claimMay combine two claims.
InterpretationreasoningThis allowed screening for constructs that increased cell abundance under different in vitro and in vivo selective pressures and high-dimensional analysis of cellular phenotypes resulting from each large knock-in DNA cassette.
“This allowed us not only to screen for constructs that increased cell abundance with different in vitro and in vivo selective pressures, but also to perform high dimensional analysis of the cellular phenotypes resulting from each large knock-in DNA cassette.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationIn mouse chronic viral infection and syngeneic tumor models, TCF7+ cells have greater proliferative potential and less differentiated phenotypes during immunotherapy.
“Consistent with this model, in mouse chronic viral infection and syngeneic tumor models, TCF7+ cells have increased proliferative potential and less differentiated phenotypes during immunotherapies (Kurtulus et al., 2019; Siddiqui et al., 2019; Wu et al., 2016)”
Quote in the paperSubstantial claim0 of 3 sources checkedMay combine two claims.
InterpretationreasoningThe paper presents a new CRISPR platform to test large knock-in candidate therapeutic constructs in primary human cells, which should accelerate development of improved cellular therapies.
“In contrast to these technologies that have shown promise for screening small mutations in immortalized cells lines, we now present a new CRISPR platform to test large knock-in candidate therapeutic constructs in primary human cells, which should accelerate the development of improved cellular therapies.”
Quote in the paperSubstantial claim- Rests on an assumption: Technical challenges have limited CRISPRa applications in therapeutically relevant primary human cell types.
- Rests on an assumption: CRISPRa can only induce natural gene products encoded in the genome and does so with variable efficiency.
May combine two claims.
PremisecitationLentiviral and retroviral vectors have variable integration copy numbers and integrate at semi-random genome sites, which can cause variable transgene expression and altered cell phenotypes through insertional mutagenesis.
“These vectors have variable integration copy numbers and integrate at semi-random genome sites, which can cause variability in transgene expression and altered cell phenotypes due to insertional mutagenesis (Cavazzana-Calvo et al., 2010; Romero et al., 2013).”
Quote in the paperSubstantial claim0 of 2 sources checked- cites Cavazzana-Calvo et al., 2010 source
Not checked in the free run.
- cites Romero et al., 2013
Not checked in the free run.
May combine two claims.
Study design and conductown dataQuality control metrics following PoKI-Seq confirmed robust rates of gene and UMI identification per cell and an average >130X coverage of cells assigned to each knock-in construct.
“Quality control metrics following PoKI-Seq confirmed robust rates of gene and UMI identification per cell and an average >130X coverage of cells assigned to each knock-in construct (per blood donor and per ex vivo condition tested) (Figure S6B–C).”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationTGFβ is a key suppressive cytokine normally produced by immune cells but can be co-opted by tumors to suppress effective immune responses.
“TGFβ is a key suppressive cytokine normally produced by immune cells but which can be co-opted by tumors to suppress effective immune responses (Batlle and Massagué, 2019; Gigante et al., 2012).”
Quote in the paperSubstantial claim0 of 2 sources checked- cites Batlle and Massagué, 2019
Not checked in the free run.
- cites Gigante et al., 2012 source
Not checked in the free run.
Classified as probably not a substantial claim.
InterpretationreasoningBarcoded knock-in libraries have broad potential to study functional effects of sequence variation at any selected site in the genome.
“Barcoded knock-in libraries have even broader potential to study functional effects of sequence variation at any selected site in the genome.”
Quote in the paperSubstantial claimMay combine two claims.
InterpretationreasoningPooled non-viral HDR templates allow targeted integration at a defined site with relatively consistent transgene expression and low rates of barcode mis-assignment without viral packaging.
“In contrast to lentiviral and retroviral transgenesis, pooled non-viral HDR templates allow for targeted integration at a defined site with relatively consistent transgene expression levels and low rates of barcode mis-assignment without requiring viral packaging steps.”
Quote in the paperSubstantial claim- Rests on an assumption: A major challenge to quantitative tracking of targeted genomic integrations of pooled knock-in constructs has been the abundance of non-integrated DNA templates in targeted cells and the risk of template switching during molecular steps of pooled library production, integration, and sequencing.
May combine two claims.
PremisecitationLentiviral and retroviral library preparation is laborious and can lead to significant barcode swapping due to viral recombination.
“In addition, lentiviral and retroviral library preparation is laborious and can lead to significant barcode swapping due to viral recombination (Sack et al., 2016).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Sack et al., 2016 source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Study design and conductcitationAll samples were processed together in one experiment, so sample origin was not regressed out.
“Of note, all samples were processed simultaneously in the same experiment and thus sample origin was not regressed out (Butler et al., 2018).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Butler et al., 2018 source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenFresh blood was taken from healthy human donors under a protocol approved by the UCSF Committee on Human Research (CHR #13-11950).
“Fresh blood was taken from healthy human donors under a protocol approved by the UCSF Committee on Human Research (CHR #13–11950).”
Quote in the paperNot a substantial claimMay combine two claims.
InterpretationreasoningWith the design parameters of the pooled knock-in library (roughly 400 bp separating the unique insert from its barcode, with the knocked-in TCR-α specificity between them), predicted switching was about 50% for pooled assembly and about 10% for pooled electroporation.
“With the parameters of the pooled knock-in library design (~400 bps between unique library insert and its corresponding barcode, separated by the new knocked in TCR-α specificity) described here (Figure 1B), the amount of predicted template switching with pooled assembly reactions was ~50%, and with a pooled electroporation condition was only ~10%.”
Quote in the paperSubstantial claim- The authors state this as an assumption: Template switching is random, and any barcode that is swapped is equally likely to switch to any other barcode.
- The authors state this as an assumption: A template that has switched once is equally likely to switch again.
Probably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenOnly cells with more than 500 detected genes were included in downstream analyses.
“Only cells with more than 500 genes identified were used for downstream analyses.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Study design and conductnone givenAll animal experiments complied with relevant ethical regulations under an approved IACUC protocol, including a 2.0 cm tumor size limit.
“All animal experiments were performed in compliance with relevant ethical regulations per an approved IACUC protocol (UCSF), including a tumor size limit of 2.0 cm in any dimension.”
Quote in the paperNot a substantial claimMay combine two claims.
InterpretationreasoningFor 1000 sorted knock-in-positive cells, 75% are predicted to have a monoallelic knock-in (750 cells, 750 alleles) and 25% a biallelic knock-in (250 cells, 500 alleles).
“Given 1000 sorted knock-in positive cells, 75% will possess a monoallelic knock-in (750 cells, 750 knock-in alleles), while 25% will possess biallelic knock-ins (250 cells, 500 knock-in alleles).”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenInvestigators were blinded to experimental treatment group during tumor sizing measurements.
“Investigators were blinded to experimental treatment group during sizing measurements.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Study design and conductnone givenReads seen fewer than twice and cells assigned more than two knock-in barcodes were removed.
“We filtered out reads appearing less than twice and cells with more than two assigned knock-in barcodes.”
Quote in the paperNot a substantial claimMay combine two claims.
InterpretationreasoningIn a two-member library, half of actual template switching involves another template with the same barcode and is undetected, so the observed switching rate must be doubled.
“In a two-member library half of the actual template switching will occur with another template that contains the same barcode, and is thus not detected. Therefore, the observed amount of switching must be multiplied by 2.”
Quote in the paperSubstantial claim- The authors state this as an assumption: Template switching is random, and any barcode that is swapped is equally likely to switch to any other barcode.
Probably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductreasoningIn each screen, donor replicates were combined for statistical analysis to address biological noise.
“All donor replicates in each screen were grouped for statistical analysis to account for biological noise.”
Quote in the paperNot a substantial claim
The paper relies on this without support.
The field lacks rapid methods to test and directly compare the functions of large DNA knock-in integrations in human primary cells.
“However, to date we have lacked rapid methods to test and directly compare the functions of large DNA knock-in integrations in human primary cells, which would accelerate the development of more effective cell therapies.”
The paper relies on this without support.
Cell abundance alone is insufficient to assess cellular function, and an ideal screening method should also assess modified cell states.
“However, cell abundance measures only one aspect of cellular function, and an ideal screening methodology would allow systematic assessment of modified cell states as well.”
The paper relies on this without support.
The in vitro conditions used in the pooled screens mimic aspects of tumor microenvironments.
“we repeated the pooled screen in diverse in vitro conditions designed to mimic aspects of tumor micro-environments”
The paper relies on this without support.
CAR T cells have not proved effective for solid tumors.
“CAR T cells are now approved therapy for some hematological malignancies, but have not proved effective for solid tumors.”
The paper relies on this without support.
For many clinical applications, engineering antigen specificity alone will not be sufficient to cure disease.
“Mounting evidence suggests that for many clinical applications engineering antigen specificity will not be sufficient to cure disease.”
The paper relies on this without support.
T cell function is often suppressed by tumors, and further engineering of antigen-specific T cells is required to promote more effective cell states.
“For example, T cell function is often suppressed by tumors and further engineering of antigen-specific T cells will be required to promote more effective cell states.”
The paper relies on this without support.
The field needs a systematic approach to compare complex transgene constructs head-to-head and determine which are most effective for specific disease indications.
“The field needs a systematic approach to compare complex transgene constructs head-to-head and determine which are most effective for specific disease indications.”
The paper relies on this without support.
Technical challenges have limited CRISPRa applications in therapeutically relevant primary human cell types.
“Technical challenges have limited CRISPRa applications in therapeutically relevant primary human cell types.”
The paper relies on this without support.
CRISPRa can only induce natural gene products encoded in the genome and does so with variable efficiency.
“Furthermore, CRISPRa can only induce natural gene products encoded in the genome and does so with variable efficiency.”
The paper relies on this without support.
A major challenge to quantitative tracking of targeted genomic integrations of pooled knock-in constructs has been the abundance of non-integrated DNA templates in targeted cells and the risk of template switching during molecular steps of pooled library production, integration, and sequencing.
“A major challenge to quantitative tracking of targeted genomic integrations of pooled knock-in constructs has been the abundance of non-integrated DNA templates (viral or non-viral) in targeted cells and the risk of template switching during molecular steps of pooled library production, integration, and sequencing.”
The paper relies on this without support.
Most over-expression studies have been performed with lentiviral or retroviral vectors.
“Most over-expression studies have been performed with lentiviral or retroviral vectors.”
The authors state this as an assumption.
Template switching is random, and any barcode that is swapped is equally likely to switch to any other barcode.
“Assumption 1: Template switching is random, and any barcode that is swapped is equally likely to switch to any other barcode.”
The authors state this as an assumption.
A template that has switched once is equally likely to switch again.
“Assumption 2: A template that has switched once is equally likely to switch again.”
The authors state this as an assumption.
The knock-in library is arbitrarily large.
“assuming an arbitrarily large knock-in library”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
PoKI-seq combines single-cell transcriptome analysis and pooled knockin screening.
“PoKI-seq [14], combines single-cell transcriptome analysis and pooled knockin screening.”
From A mini-review on perturbation modelling across single-cell omic modalities (2024) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Cancer-cell clearance ratio is interpreted backward
MajorDividing control-cell clearance by experimental-cell clearance makes a value above 1 mean the experimental cells cleared fewer cancer cells than the control cells, not more. This reverses the stated interpretation of the assay's outcome.
“The control T cell population clearance value was divided by the experimental T cell population clearance value”
“an A375 clearance value greater than 1 indicates more cancer cell killing relative to control T cells, while a value less than 1 indicates decreased cancer cell killing relative to control T cells.”
PoKI-Seq library and processing versions conflict
MinorThe PoKI-Seq methods specify v3 single-cell chemistry and Cell Ranger 3.0.2, while the PoKI-Seq analysis describes V2 libraries processed with CellRanger 2.0.0. The text does not distinguish separate datasets that would account for these differing specifications.
“Single-cell RNA sequencing was performed on 8 separate samples (2 donors, 2 recipients per donor, matched pre- and post-implantation cells) with the Chromium Single Cell 3′ Reagent Kit, v3 chemistry (10x Genomics, PN-1000092)”
“Pre-processing of the Illumina sequencing results from the 10X Genomics V2 libraries was performed with CellRanger software, version 2.0.0.”
In vivo PoKI-Seq cites the wrong method figure
MinorThe in vivo account points to Figure 4A for combined single-cell amplicon and RNA sequencing, while the paper introduces that PoKI-Seq method at Figure 5A.
“PoKI-Seq with combined single cell amplicon and RNA-sequencing (Figure 4A).”
“We next tested whether pooled knock-in screening could similarly be coupled with scRNA-seq to generate high-dimensional phenotypic information on modified cell states while also recording each cell’s specific knock-in construct barcodes, a method we term PoKI-Seq (Pooled Knock-In Sequencing) (Figure 5A).”
Cites
Integrating single-cell transcriptomic data across different conditions, technologies, and species
Butler, A., Hoffman, P., Smibert, P., Papalexi, E., & Satija, R. (2018) · Nature Biotechnology · doi:10.1038/nbt.4096 · Cited by 13,174 · see citing works
Massively parallel digital transcriptional profiling of single cells
Zheng, G. X. Y., Terry, J. M., Belgrader, P., Ryvkin, P., Bent, Z. W., Wilson, R., Ziraldo, S. B., Wheeler, T. D., McDermott, G. P., Zhu, J., et al. (2017) · Nature Communications · doi:10.1038/ncomms14049 · Cited by 7,353 · see citing works
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · see citing works
Understanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145 · see citing works
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234 · see citing works
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · see citing works
Fast gene set enrichment analysisPreprint
Korotkevich, G., Sukhov, V., Budin, N., Shpak, B., Artyomov, M. N., & Sergushichev, A. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/060012 · Cited by 3,742 · see citing works
CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes
Gilbert, L. A., Larson, M. H., Morsut, L., Liu, Z., Brar, G. A., Torres, S. E., Stern-Ginossar, N., Brandman, O., Whitehead, E. H., Doudna, J. A., et al. (2013) · Cell · doi:10.1016/j.cell.2013.06.044 · Cited by 3,696 · see citing works
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237 · see citing works
Genetic screens in human cells using the CRISPR-Cas9 system
Wang, T., Wei, J. J., Sabatini, D. M., & Lander, E. S. (2014) · Science · doi:10.1126/science.1246981 · Cited by 2,856 · see citing works
The Reactome Pathway Knowledgebase
Fabregat, A., Jupe, S., Matthews, L. R., Sidiropoulos, K., Gillespie, M. E., Garapati, P. V., Haw, R., Jassal, B., Korninger, F., May, B., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx1132 · Cited by 2,798 · see citing works
Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation
Gilbert, L. A., Horlbeck, M. A., Adamson, B., Villalta, J. E., Chen, Y., Whitehead, E. H., Guimaraes, C., Panning, B., Ploegh, H. L., Bassik, M. C., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.029 · Cited by 2,728 · see citing works
Transforming Growth Factor-β Signaling in Immunity and Cancer
Batlle, E., & Massagué, J. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.024 · Cited by 2,366 · see citing works
Chimeric Antigen Receptor Therapy
June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,355 · see citing works
Dixit, A., Parnas, O., Li, B., Chen, J., Fulco, C. P., Jerby-Arnon, L., Marjanovic, N. D., Dionne, D., Burks, T., Raychowdhury, R., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.038 · Cited by 1,863 · see citing works
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831 · see citing works
Siddiqui, I., Schaeuble, K., Chennupati, V., Fuertes Marraco, S. A., Calderon-Copete, S., Pais Ferreira, D., Carmona, S. J., Scarpellino, L., Gfeller, D., Pradervand, S., et al. (2019) · Immunity · doi:10.1016/j.immuni.2018.12.021 · Cited by 1,679 · see citing works
TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion
Khan, O., Giles, J. R., McDonald, S., Manne, S., Ngiow, S. F., Patel, K. P., Werner, M. T., Huang, A. C., Alexander, K. A., Wu, J. E., et al. (2019) · Nature · doi:10.1038/s41586-019-1325-x · Cited by 1,646 · see citing works
Highly efficient Cas9-mediated transcriptional programming
Chavez, A., Scheiman, J., Vora, S., Pruitt, B. W., Tuttle, M., P R Iyer, E., Lin, S., Kiani, S., Guzman, C. D., Wiegand, D. J., et al. (2015) · Nature Methods · doi:10.1038/nmeth.3312 · Cited by 1,622 · see citing works
CRISPR-engineered T cells in patients with refractory cancer
Stadtmauer, E. A., Fraietta, J. A., Davis, M. M., Cohen, A. D., Weber, K. L., Lancaster, E., Mangan, P. A., Kulikovskaya, I., Gupta, M., Chen, F., et al. (2020) · Science · doi:10.1126/science.aba7365 · Cited by 1,478 · see citing works
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,477 · see citing works
TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance
Thomas, D. A., & Massagué, J. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.012 · Cited by 1,355 · see citing works
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature reviews. Immunology · doi:10.1038/nri2744 · Cited by 1,282 · see citing works
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276 · see citing works
The Reactome pathway Knowledgebase
Fabregat, A., Sidiropoulos, K., Garapati, P., Gillespie, M., Hausmann, K., Haw, R., Jassal, B., Jupe, S., Korninger, F., McKay, S., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1351 · Cited by 1,201 · see citing works
Adamson, B., Norman, T. M., Jost, M., Cho, M. Y., Nuñez, J. K., Chen, Y., Villalta, J. E., Gilbert, L. A., Horlbeck, M. A., Hein, M. Y., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.048 · Cited by 1,193 · see citing works
Pooled CRISPR screening with single-cell transcriptome readout.
Datlinger, P., Rendeiro, A. F., Schmidl, C., Krausgruber, T., Traxler, P., Klughammer, J., Schuster, L. C., Kuchler, A., Alpar, D., & Bock, C. (2017) · Nature Methods · doi:10.1038/nmeth.4177 · Cited by 1,096 · see citing works
Engineered T cells: the promise and challenges of cancer immunotherapy
Fesnak, A. D., June, C. H., & Levine, B. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.97 · Cited by 1,074 · see citing works
The many roles of FAS receptor signaling in the immune system
Strasser, A., Jost, P. J., & Nagata, S. (2009) · Immunity · doi:10.1016/j.immuni.2009.01.001 · Cited by 968 · see citing works
Gorelik, L., & Flavell, R. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80170-3 · Cited by 959 · see citing works
Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9
Paquet, D., Kwart, D., Chen, A., Sproul, A., Jacob, S., Teo, S., Olsen, K. M., Gregg, A., Noggle, S., & Tessier-Lavigne, M. (2016) · Nature · doi:10.1038/nature17664 · Cited by 951 · see citing works
Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition
Ren, J., Liu, X., Fang, C., Jiang, S., June, C. H., & Zhao, Y. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1300 · Cited by 942 · see citing works
c-Jun overexpression in CAR T cells induces exhaustion resistance
Lynn, R. C., Weber, E. W., Sotillo, E., Gennert, D., Xu, P., Good, Z., Anbunathan, H., Lattin, J., Jones, R., Tieu, V., et al. (2019) · Nature · doi:10.1038/s41586-019-1805-z · Cited by 891 · see citing works
Therapeutic T cell engineering
Sadelain, M., Rivière, I., & Riddell, S. R. (2017) · Nature · doi:10.1038/nature22395 · Cited by 886 · see citing works
Accurate classification of BRCA1 variants with saturation genome editing
Findlay, G. M., Daza, R. M., Martin, B., Zhang, M. D., Leith, A. P., Gasperini, M., Janizek, J. D., Huang, X., Starita, L. M., & Shendure, J. (2018) · Nature · doi:10.1038/s41586-018-0461-z · Cited by 843 · see citing works
Reprogramming human T cell function and specificity with non-viral genome targeting
Roth, T. L., Puig-Saus, C., Yu, R., Shifrut, E., Carnevale, J., Li, P. J., Hiatt, J., Saco, J., Krystofinski, P., Li, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0326-5 · Cited by 839 · see citing works
Self-citationDissecting Immune Circuits by Linking CRISPR-Pooled Screens with Single-Cell RNA-Seq
Jaitin, D. A., Weiner, A., Yofe, I., Lara-Astiaso, D., Keren-Shaul, H., David, E., Salame, T. M., Tanay, A., van Oudenaarden, A., & Amit, I. (2016) · Cell · doi:10.1016/j.cell.2016.11.039 · Cited by 777 · see citing works
Rupp, L. J., Schumann, K., Roybal, K. T., Gate, R. E., Ye, C. J., Lim, W. A., & Marson, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-00462-8 · Cited by 757 · see citing works
Self-citationObstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies
Anderson, K. G., Stromnes, I. M., & Greenberg, P. D. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.008 · Cited by 706 · see citing works
Kloss, C. C., Lee, J., Zhang, A., Chen, F., Melenhorst, J. J., Lacey, S. F., Maus, M. V., Fraietta, J. A., Zhao, Y., & June, C. H. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.003 · Cited by 648 · see citing works
Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1-CD8+ Tumor-Infiltrating T Cells
Kurtulus, S., Madi, A., Escobar, G., Klapholz, M., Nyman, J., Christian, E., Pawlak, M., Dionne, D., Xia, J., Rozenblatt-Rosen, O., et al. (2019) · Immunity · doi:10.1016/j.immuni.2018.11.014 · Cited by 636 · see citing works
The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness
Wu, T., Ji, Y., Moseman, E. A., Xu, H. C., Manglani, M., Kirby, M., Anderson, S. M., Handon, R., Kenyon, E., Elkahloun, A. G., et al. (2016) · Science Immunology · doi:10.1126/sciimmunol.aai8593 · Cited by 614 · see citing works
Ostrand-Rosenberg, S., Sinha, P., Beury, D. W., & Clements, V. K. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.01.011 · Cited by 583 · see citing works
Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function
Shifrut, E., Carnevale, J., Tobin, V., Roth, T. L., Woo, J. M., Bui, C. T., Li, P. J., Diolaiti, M. E., Ashworth, A., & Marson, A. (2018) · Cell · doi:10.1016/j.cell.2018.10.024 · Cited by 573 · see citing works
Self-citationMorgan, M. T., Anders, S., Lawrence, M. F., Aboyoun, P., Pagès, H., & Gentleman, R. C. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp450 · Cited by 545 · see citing works
Liu, X., Ranganathan, R., Jiang, S., Fang, C., Sun, J., Kim, S., Newick, K., Lo, A., June, C. H., Zhao, Y., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2524 · Cited by 524 · see citing works
Directed evolution using dCas9-targeted somatic hypermutation in mammalian cells
Hess, G. T., Frésard, L., Han, K., Lee, C. H., Li, A., Cimprich, K. A., Montgomery, S. B., & Bassik, M. C. (2016) · Nature Methods · doi:10.1038/nmeth.4038 · Cited by 469 · see citing works
Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy
Wei, J., Long, L., Zheng, W., Dhungana, Y., Lim, S. A., Guy, C. S., Wang, Y., Wang, Y., Qian, C., Xu, B., et al. (2019) · Nature · doi:10.1038/s41586-019-1821-z · Cited by 442 · see citing works
Targeted AID-mediated mutagenesis (TAM) enables efficient genomic diversification in mammalian cells
Ma, Y., Zhang, J., Yin, W., Zhang, Z., Song, Y., & Chang, X. (2016) · Nature Methods · doi:10.1038/nmeth.4027 · Cited by 415 · see citing works
Cell-Based Therapeutics: The Next Pillar of Medicine
Fischbach, M., Bluestone, J., & Lim, W. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005568 · Cited by 410 · see citing works
Self-citationSaturation editing of genomic regions by multiplex homology-directed repair
Findlay, G. M., Boyle, E. A., Hause, R. J., Klein, J. C., & Shendure, J. (2014) · Nature · doi:10.1038/nature13695 · Cited by 362 · see citing works
Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells
Dong, M. B., Wang, G., Chow, R. D., Ye, L., Zhu, L., Dai, X., Park, J. J., Kim, H. R., Errami, Y., Guzman, C. D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.07.044 · Cited by 330 · see citing works
Nguyen, D. N., Roth, T. L., Li, P. J., Chen, P. A., Apathy, R., Mamedov, M. R., Vo, L. T., Tobin, V. R., Goodman, D. B., Shifrut, E., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0325-6 · Cited by 315 · see citing works
Self-citationCRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
Su, S., Hu, B., Shao, J., Shen, B., Du, J., Du, Y., Zhou, J., Yu, L., Zhang, L., Chen, F., et al. (2016) · Scientific Reports · doi:10.1038/srep20070 · Cited by 310 · see citing works
TGF-β in T Cell Biology: Implications for Cancer Immunotherapy
Dahmani, A., & Delisle, J. (2018) · Cancers · doi:10.3390/cancers10060194 · Cited by 216 · see citing works
Prosser, M. E., Brown, C. E., Shami, A. F., Forman, S. J., & Jensen, M. C. (2012) · Molecular Immunology · doi:10.1016/j.molimm.2012.03.023 · Cited by 186 · see citing works
Reversal of tumor immune inhibition using a chimeric cytokine receptor.
Leen, A., Sukumaran, S., Watanabe, N., Mohammed, S., Keirnan, J., Yanagisawa, R., Anurathapan, U., Rendon, D. A., Heslop, H., Rooney, C., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.47 · Cited by 171 · see citing works
T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy
Yamamoto, T. N., Lee, P.-H., Vodnala, S. K., Gurusamy, D., Kishton, R. J., Yu, Z., Eidizadeh, A., Eil, R., Fioravanti, J., Gattinoni, L., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci121491 · Cited by 156 · see citing works
CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy
Chen, N., Morello, A., Tano, Z. E., & Adusumilli, P. S. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1273302 · Cited by 134 · see citing works
β-globin gene transfer to human bone marrow for sickle cell disease
Romero, Z. G., Urbinati, F., Geiger, S., Cooper, A. R., Wherley, J., Kaufman, M. L., Hollis, R. P., de Assín, R. R., Senadheera, S., Sahagian, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67930 · Cited by 107 · see citing works
Shin, J. H., Park, H. B., Oh, Y. M., Lim, D. P., Lee, J. E., Seo, H. H., Lee, S. J., Eom, H., Kim, I.-H., Lee, S. H., et al. (2012) · Blood · doi:10.1182/blood-2011-09-380519 · Cited by 82 · see citing works
Genome-scale CRISPR pooled screens
Sanjana, N. E. (2016) · Analytical Biochemistry · doi:10.1016/j.ab.2016.05.014 · Cited by 77 · see citing works
Sources of Error in Mammalian Genetic Screens
Sack, L. M., Davoli, T., Xu, Q., Li, M. Z., & Elledge, S. J. (2016) · G3 Genes|Genomes|Genetics · doi:10.1534/g3.116.030973 · Cited by 76 · see citing works
Hegde, M., Strand, C., Hanna, R. E., & Doench, J. G. (2018) · PLOS ONE · doi:10.1371/journal.pone.0197547 · Cited by 66 · see citing works
Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials
Esensten, J. H., Bluestone, J. A., & Lim, W. A. (2017) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100304 · Cited by 62 · see citing works
Self-citationOda, S. K., Daman, A. W., Garcia, N. M., Wagener, F. D., Schmitt, T. M., Tan, X., Chapuis, A. G., & Greenberg, P. D. (2017) · Blood · doi:10.1182/blood-2017-04-777052 · Cited by 62 · see citing works
Feldman, D., Singh, A., Garrity, A. J., & Blainey, P. C. (2018) · doi:10.1101/262121 · Cited by 49 · see citing works
TGF-beta: a master switch in tumor immunity
Gigante, M., Gesualdo, L., & Ranieri, E. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802430378 · Cited by 45 · see citing works
Kim, S. K., Barron, L., Hinck, C. S., Petrunak, E. M., Cano, K. E., Thangirala, A., Iskra, B., Brothers, M., Vonberg, M., Leal, B., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.768754 · Cited by 43 · see citing works
Gwiazda, K., Grier, A. E., Sahni, J., Burleigh, S. M., Martin, U., Yang, J., Popp, N. A., Krutein, M. C., Khan, I., Jacoby, K., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.105 · Cited by 34 · see citing works
Reprogramming cellular functions with engineered membrane proteins
Arber, C., Young, M., & Barth, P. (2017) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2017.06.009 · Cited by 22 · see citing works
Hanna, R. E., & Doench, J. G. (2018) · Nature Biotechnology · doi:10.1038/nbt.4208 · Cited by 22 · see citing works
Chimeric Switch Receptor: Switching for Improved Adoptive T-Cell Therapy Against Cancers
Tay, J. C., Zha, S., & Wang, S. (2017) · Immunotherapy · doi:10.2217/imt-2017-0103 · Cited by 16 · see citing works
Enhanced Anti-tumor Reactivity of Cytotoxic T Lymphocytes Expressing PD-1 Decoy
Shin, J. H., Park, H. B., & Choi, K. (2016) · Immune Network · doi:10.4110/in.2016.16.2.134 · Cited by 9 · see citing works
Nguyen, D. N., Roth, T. L., Li, J., Chen, P. A., Mamedov, M. R., Vo, L. T., Tobin, V. R., Apathy, R., Goodman, D. B., Shifrut, E., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/591719 · Cited by 5 · see citing works
Self-citation
Flagged first, then by citations
2 of the 77 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
CD8+ T cell differentiation and dysfunction in cancer
Philip, M., & Schietinger, A. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00574-3 · Cited by 1,052 · see citing works
Natural killer cells in antitumour adoptive cell immunotherapy
Laskowski, T. J., Biederstadt, A., & Rezvani, K. (2022) · Nature Reviews. Cancer · doi:10.1038/s41568-022-00491-0 · Cited by 680 · see citing works
Targeting the epigenetic regulation of antitumour immunity
Hogg, S. J., Beavis, P. A., Dawson, M. A., & Johnstone, R. W. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0077-5 · Cited by 653 · see citing works
Engineering CAR-T Cells for Next-Generation Cancer Therapy
Hong, M., Clubb, J. D., & Chen, Y. Y. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.005 · Cited by 644 · see citing works
Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1-CD8+ Tumor-Infiltrating T Cells
Kurtulus, S., Madi, A., Escobar, G., Klapholz, M., Nyman, J., Christian, E., Pawlak, M., Dionne, D., Xia, J., Rozenblatt-Rosen, O., et al. (2019) · Immunity · doi:10.1016/j.immuni.2018.11.014 · Cited by 636 · see citing works
Navigating CAR-T cells through the solid-tumour microenvironment
Hou, A. J., Chen, L. C., & Chen, Y. Y. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00189-2 · Cited by 556 · see citing works
Engineering the next generation of cell-based therapeutics
Bashor, C. J., Hilton, I. B., Bandukwala, H. S., Smith, D. M., & Omid Veiseh, A. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00476-6 · Cited by 448 · see citing works
Targeting TGFβ signal transduction for cancer therapy
Liu, S., Ren, J., & ten Dijke, P. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00436-9 · Cited by 413 · see citing works
An NK-like CAR T cell transition in CAR T cell dysfunction
Good, C. R., Aznar, M. A., Kuramitsu, S., Samareh, P., Agarwal, S., Donahue, G., Ishiyama, K., Wellhausen, N., Rennels, A. K., Ma, Y., et al. (2021) · Cell · doi:10.1016/j.cell.2021.11.016 · Cited by 396 · see citing works
Belk, J. A., Yao, W., Ly, N., Freitas, K. A., Chen, Y.-T., Shi, Q., Valencia, A. M., Shifrut, E., Kale, N., Yost, K. E., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.06.001 · Cited by 382 · see citing works
Self-citationOvercoming TGFβ-mediated immune evasion in cancer
Tauriello, D. V. F., Sancho, E., & Batlle, E. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00413-6 · Cited by 377 · see citing works
Epigenetic regulation of T cell exhaustion
Belk, J. A., Dániel, B., & Satpathy, A. T. (2022) · Nature Immunology · doi:10.1038/s41590-022-01224-z · Cited by 334 · see citing works
A new era in functional genomics screens
Przybyla, L., & Gilbert, L. A. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00409-w · Cited by 281 · see citing works
FOXO1 is a master regulator of memory programming in CAR T cells
Doan, A. E., Mueller, K. P., Chen, A. Y., Rouin, G. T., Chen, Y.-S., Daniel, B., Lattin, J., Markovska, M., Mozarsky, B., Arias-Umana, J., et al. (2024) · Nature · doi:10.1038/s41586-024-07300-8 · Cited by 210 · see citing works
Shy, B., Vykunta, V. S., Ha, A. S., Talbot, A., Roth, T. L., Nguyen, D. N., Pfeifer, W. G., Chen, Y.-Y., Blaeschke, F., Shifrut, E., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01418-8 · Cited by 182 · see citing works
Self-citationWienke, J., Dierselhuis, M. P., Tytgat, G. A. M., Künkele, A., Nierkens, S., & Molenaar, J. J. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.11.014 · Cited by 216 · see citing works
CRISPR-based genome editing through the lens of DNA repair
Nambiar, T. S., Baudrier, L., Billon, P., & Ciccia, A. (2022) · Molecular Cell · doi:10.1016/j.molcel.2021.12.026 · Cited by 214 · see citing works
Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy
Liu, Z., Zhou, Z., Dang, Q., Xu, H. M., Lv, J., Li, H., & Han, X. (2022) · Theranostics · doi:10.7150/thno.76854 · Cited by 198 · see citing works
Johnson, L. R., Lee, D. Y., Eacret, J. S., Ye, D., June, C. H., & Minn, A. J. (2021) · Cell · doi:10.1016/j.cell.2021.08.004 · Cited by 189 · see citing works
A genome-scale screen for synthetic drivers of T cell proliferation
Legut, M., Gajic, Z. Z., Guarino, M., Daniloski, Z., Rahman, J. A., Xue, X., Lu, C., Lu, L., Mimitou, E. P., Hao, S., et al. (2022) · Nature · doi:10.1038/s41586-022-04494-7 · Cited by 177 · see citing works
Next-Generation CAR T-cell Therapies
Young, R. M., Engel, N. W., Uslu, U., Wellhausen, N., & June, C. H. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1683 · Cited by 182 · see citing works
Genetic engineering of T cells for immunotherapy
Ellis, G. I., Sheppard, N. C., & Riley, J. L. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00329-9 · Cited by 166 · see citing works
T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome
Klebanoff, C. A., Chandran, S. S., Baker, B. M., Quezada, S. A., & Ribas, A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00809-z · Cited by 158 · see citing works
Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy
Liu, Z., Shi, M., Ren, Y., Xu, H., Weng, S., Ning, W., Ge, X., Liu, L., Guo, C., Duo, M., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01738-6 · Cited by 146 · see citing works
TGFβ control of immune responses in cancer: a holistic immuno-oncology perspective
Nixon, B. G., Gao, S., Wang, X., & Li, M. O. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00796-z · Cited by 138 · see citing works
Advancing CAR T cell therapy through the use of multidimensional omics data
Yang, J., Chen, Y., Jing, Y., Green, M. R., & Han, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00729-2 · Cited by 128 · see citing works
An evolved AAV variant enables efficient genetic engineering of murine T cells
Nyberg, W. A., Ark, J., To, A., Clouden, S., Reeder, G. C., Muldoon, J. J., Chung, J.-Y., Xie, W. H., Allain, V., Steinhart, Z., et al. (2023) · Cell · doi:10.1016/j.cell.2022.12.022 · Cited by 110 · see citing works
Integration of CRISPR/Cas9 with artificial intelligence for improved cancer therapeutics
Bhat, A. A., Nisar, S., Mukherjee, S., Saha, N., Yarravarapu, N., Lone, S. N., Masoodi, T., Chauhan, R., Maacha, S., Bagga, P., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03765-1 · Cited by 108 · see citing works
Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR T cells
Kath, J., Du, W., Pruene, A., Braun, T., Thommandru, B., Turk, R., Sturgeon, M. L., Kurgan, G., Amini, L., Stein, M., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.03.018 · Cited by 95 · see citing works
Goodman, D. B., Azimi, C. S., Kearns, K., Talbot, A., Garakani, K., Garcia, J. M., Patel, N. A., Hwang, B., Lee, D. S., Park, M., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abm1463 · Cited by 98 · see citing works
Self-citationBase-editing mutagenesis maps alleles to tune human T cell functions
Schmidt, R. L. J., Ward, C. C., Dajani, R., Armour-Garb, Z., Ota, M., Allain, V., Hernandez, R., Layeghi, M., Xing, G. K., Goudy, L., et al. (2023) · Nature · doi:10.1038/s41586-023-06835-6 · Cited by 98 · see citing works
Self-citationFreimer, J. W., Shaked, O., Naqvi, S., Sinnott-Armstrong, N., Kathiria, A. S., Garrido, C. M., Chen, A. F., Cortez, J. T., Greenleaf, W. J., Pritchard, J. K., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01106-y · Cited by 93 · see citing works
Self-citationA new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy
Li, N., Geng, S., Dong, Z., Jin, Y., Ying, H., Li, H., & Shi, L. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02032-9 · Cited by 104 · see citing works
Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy
Rath, J. A., & Arber, C. (2020) · Cells · doi:10.3390/cells9061485 · Cited by 99 · see citing works
TCF-1 regulates HIV-specific CD8+ T cell expansion capacity
Rutishauser, R. L., Deguit, C. D. T., Hiatt, J. B., Blaeschke, F., Roth, T. L., Wang, L., Raymond, K. A., Starke, C. E., Mudd, J. C., Chen, W., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.136648 · Cited by 93 · see citing works
Self-citationSingle-cell omics: experimental workflow, data analyses and applications
Sun, F., Li, H., Sun, D., Fu, S., Gu, L., Shao, X., Wang, Q., Dong, X., Duan, B., Xing, F., et al. (2024) · Science China Life Sciences · doi:10.1007/s11427-023-2561-0 · Cited by 81 · see citing works
Engineering approaches for RNA-based and cell-based osteoarthritis therapies
DeJulius, C. R., Walton, B. L., Colazo, J. M., d’Arcy, R., Francini, N., Brunger, J. M., & Duvall, C. L. (2024) · Nature Reviews Rheumatology · doi:10.1038/s41584-023-01067-4 · Cited by 81 · see citing works
Engineered receptors for soluble cellular communication and disease sensing
Piraner, D. I., Abedi, M. H., Gonzalez, M. J. D., Chazin-Gray, A. M., Lin, A. J., Zhu, I., Ravindran, P. T., Schlichthaerle, T., Huang, B., Bearchild, T. H., et al. (2024) · Nature · doi:10.1038/s41586-024-08366-0 · Cited by 72 · see citing works
Self-citationModular pooled discovery of synthetic knockin sequences to program durable cell therapies
Blaeschke, F., Chen, Y. Y., Apathy, R., Dániel, B., Chen, A. Y., Chen, P. A., Sándor, K., Zhang, W., Li, Z., Mowery, C. T., et al. (2023) · Cell · doi:10.1016/j.cell.2023.08.013 · Cited by 69 · see citing works
Self-citationTGF-β and Cancer Immunotherapy
Maruyama, T., Chen, W., & Shibata, H. (2022) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b21-00966 · Cited by 68 · see citing works
HIF regulates multiple translated endogenous retroviruses: Implications for cancer immunotherapy
Jiang, Q., Braun, D. A., Clauser, K. R., Ramesh, V., Shirole, N. H., Duke-Cohan, J. E., Nabilsi, N., Kramer, N. J., Forman, C., Lippincott, I. E., et al. (2025) · Cell · doi:10.1016/j.cell.2025.01.046 · Cited by 68 · see citing works
DCision-making in tumors governs T cell anti-tumor immunity
Alfei, F., Ho, P., & Lo, W. (2021) · Oncogene · doi:10.1038/s41388-021-01946-8 · Cited by 67 · see citing works
Preclinical Evaluation of CAR T Cell Function: In Vitro and In Vivo Models
Si, X., Xiao, L., Brown, C. E., & Wang, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063154 · Cited by 69 · see citing works
Expression of inducible factors reprograms CAR-T cells for enhanced function and safety
Smole, A., Benton, A., Poussin, M., Eiva, M. A., Mezzanotte, C., Camisa, B., Greco, B. M., Sharma, P., Minutolo, N. G., Gray, F., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.11.006 · Cited by 67 · see citing works
Wagner, D., Koehl, U., Chmielewski, M., Scheid, C., & Stripecke, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.865424 · Cited by 53 · see citing works
Mueller, K. P., Piscopo, N. J., Forsberg, M. H., Saraspe, L. A., Das, A., Russell, B. E., Smerchansky, M. E., Cappabianca, D., Shi, L., Shankar, K., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004446 · Cited by 61 · see citing works
Roth, T. L., & Marson, A. (2021) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012419-032626 · Cited by 64 · see citing works
Self-citationA Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy
Oda, S. K., Anderson, K. G., Ravikumar, P., Bonson, P., Garcia, N. M., Jenkins, C. M., Zhuang, S., Daman, A. W., Chiu, E. Y., Bates, B. M., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20191166 · Cited by 61 · see citing works
In vivo functional screening for systems-level integrative cancer genomics
Weber, J., Braun, C. J., Saur, D., & Rad, R. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0275-9 · Cited by 57 · see citing works
Castellanos-Rueda, R., Roberto, R. B. D., Bieberich, F., Schlatter, F. S., Palianina, D., Nguyen, O. T. P., Kapetanovic, E., Laubli, H. P., Hierlemann, A. R., Khanna, N., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34141-8 · Cited by 61 · see citing works
Microenvironmental regulation of solid tumour resistance to CAR T cell therapy
Lamplugh, Z. L., Wellhausen, N., June, C. H., & Fan, Y. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01229-3 · Cited by 71 · see citing works
The outstanding antitumor capacity of CD4+ T helper lymphocytes
Li, T., Wu, B., Yang, T., Zhang, L., & Jin, K. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188439 · Cited by 57 · see citing works
Engineered natural killer cells for cancer therapy
Biederstädt, A., & Rezvani, K. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.09.013 · Cited by 59 · see citing works
A mini-review on perturbation modelling across single-cell omic modalities
Gavriilidis, G. I., Vasileiou, V., Orfanou, A., Ishaque, N., & Psomopoulos, F. (2024) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2024.04.058 · Cited by 54 · see citing works
Ma, Q., He, X., Zhang, B., Guo, F., Ou, X., Yang, Q., Shu, P., Chen, Y., Li, K., Gao, G., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01198-2 · Cited by 55 · see citing works
Emerging Strategies in TCR-Engineered T Cells
Fang, W., Cheng, X., Xue, J. Z., & Xue, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.850358 · Cited by 54 · see citing works
Massively parallel knock-in engineering of human T cells
Dai, X., Park, J. J.-Y., Du, Y., Na, Z., Lam, S. Z., Chow, R. D.-W., Renauer, P. A., Gu, J., Shan, X., Chu, Z., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01639-x · Cited by 54 · see citing works
Patino, C. A., Pathak, N., Mukherjee, P., Park, S. H., Bao, G., & Espinosa, H. D. (2022) · Science Advances · doi:10.1126/sciadv.abn7637 · Cited by 50 · see citing works
CAR-engineered lymphocyte persistence is governed by a FAS ligand–FAS autoregulatory circuit
Yi, F., Cohen, T., Zimmerman, N., Dündar, F., Zumbo, P., Eltilib, R., Brophy, E. J., Arkin, H., Feucht, J., Gormally, M. V., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-01009-x · Cited by 52 · see citing works
Allemailem, K. S., Alsahli, M. A., Almatroudi, A., Alrumaihi, F., Abdulmonem, W. A., Moawad, A. A., Alwanian, W. M., Almansour, N. M., Rahmani, A. H., & Khan, A. A. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s424872 · Cited by 47 · see citing works
CRISPR/Cas9-Mediated Genome Editing in Cancer Therapy
Ding, S., Liu, J., Han, X., & Tang, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216325 · Cited by 42 · see citing works
Massively Parallel CRISPR‐Based Genetic Perturbation Screening at Single‐Cell Resolution
Cheng, J., Lin, G., Wang, T., Wang, Y., Guo, W., Liao, J., Yang, P., Chen, J., Shao, X., Lu, X., et al. (2022) · Advanced Science · doi:10.1002/advs.202204484 · Cited by 40 · see citing works
Engineered Treg cells: The heir to the throne of immunotherapy
Stucchi, A., Maspes, F., Montee-Rodrigues, E., & Fousteri, G. (2023) · Journal of Autoimmunity · doi:10.1016/j.jaut.2022.102986 · Cited by 43 · see citing works
Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy
Marone, R., Landmann, E., Devaux, A., Lepore, R., Seyres, D., Zuin, J., Burgold, T., Engdahl, C., Capoferri, G., Dell’Aglio, A., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20231235 · Cited by 40 · see citing works
Exploiting the CRISPR‐Cas9 gene‐editing system for human cancers and immunotherapy
Afolabi, L. O., Afolabi, M. O., Sani, M. M., Okunowo, W. O., Yan, D., Chen, L., Zhang, Y., & Wan, X. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1286 · Cited by 43 · see citing works
Function and evolution of the prototypic CD28ζ and 4-1BBζ chimeric antigen receptors
Feucht, J., & Sadelain, M. (2020) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2020.09.001 · Cited by 36 · see citing works
Genetic Engineering of Natural Killer Cells for Enhanced Antitumor Function
Mantesso, S., Geerts, D., Spanholtz, J., & Kučerová, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.607131 · Cited by 36 · see citing works
Wang, C., Cheng, J. K. W., Zhang, Q., Hughes, N. W., Xia, Q., Winslow, M. M., & Cong, L. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa1264 · Cited by 36 · see citing works
Tutorial: design and execution of CRISPR in vivo screens
Braun, C. J., Adames, A. C., Saur, D., & Rad, R. (2022) · Nature Protocols · doi:10.1038/s41596-022-00700-y · Cited by 35 · see citing works
CAR‐T‐cell products in solid tumors: Progress, challenges, and strategies
Qian, K., Li, G., Zhang, S., Fu, W., Li, T., Zhao, J., Lei, C., Wang, Y., & Hu, S. (2024) · Interdisciplinary medicine · doi:10.1002/inmd.20230047 · Cited by 34 · see citing works
Engineering CAR T cells for enhanced efficacy and safety
Wu, Y., Huang, Z., Harrison, R. E. S., Liu, L., Zhu, L., Situ, Y., & Wang, Y. (2022) · APL Bioengineering · doi:10.1063/5.0073746 · Cited by 34 · see citing works
CRISPR screen in cancer: status quo and future perspectives.
He, C., Han, S., Chang, Y., Wu, M., Zhao, Y., Chen, C. Y., & Chu, X. (2021) · PubMed Central · Cited by 32 · see citing works
Challenges of CRISPR-Based Gene Editing in Primary T Cells
Rezalotfi, A., Fritz, L. V., Förster, R., & Bošnjak, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031689 · Cited by 33 · see citing works
Tumor immunology CRISPR screening: present, past, and future
Dong, M. B., Tang, K., Zhou, X., Zhou, J. J., & Chen, S. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.11.009 · Cited by 31 · see citing works
Mog, B. J., Marcou, N., DiNapoli, S. R., Pearlman, A. H., Nichakawade, T. D., Hwang, M. S., Douglass, J., Hsiue, E. H.-C., Glavaris, S. A., Wright, K. M., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adg7123 · Cited by 30 · see citing works
Strengthening the CAR‐T cell therapeutic application using CRISPR/Cas9 technology
Nezhad, M. S., Yazdanifar, M., Abdollahpour‐Alitappeh, M., Sattari, A., Seifalian, A. M., & Bagheri, N. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.27882 · Cited by 30 · see citing works
Novel Mouse Models for Cancer Immunology
Connolly, K. A., Fitzgerald, B., Damo, M., & Joshi, N. S. (2022) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070620-105523 · Cited by 30 · see citing works
Novel extragenic genomic safe harbors for precise therapeutic T cell engineering
Odak, A., Yuan, H., Feucht, J., Cantu, A., Mansilla‐Soto, J., Kogel, F., Eyquem, J., Everett, J. K., Bushman, F. D., Leslie, C. S., et al. (2023) · Blood · doi:10.1182/blood.2022018924 · Cited by 29 · see citing works
Coengineering specificity, safety, and function into T cells for cancer immunotherapy
Attianese, G. M. P. G., Ash, S., & Irving, M. B. (2023) · Immunological Reviews · doi:10.1111/imr.13252 · Cited by 29 · see citing works
T-Cell Gene Therapy in Cancer Immunotherapy: Why It Is No Longer Just CARs on The Road
Crowther, M. D., Svane, I. M., & Met, Ö. (2020) · Cells · doi:10.3390/cells9071588 · Cited by 28 · see citing works
Adoptive Cellular Therapy for Solid Tumors
Bear, A. S., Fraietta, J. A., Narayan, V., O’Hara, M. H., & Haas, N. B. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_321115 · Cited by 27 · see citing works
Anderson, K. G., Oda, S. K., Bates, B. M., Burnett, M. G., Suarez, M. L. R., Ruskin, S. L., & Greenberg, P. D. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003959 · Cited by 28 · see citing works
Leveraging Single-Cell Sequencing for Chimeric Antigen Receptor T Cell Therapies
Castellanos-Rueda, R., Roberto, R. B. D., Schlatter, F. S., & Reddy, S. T. (2021) · Trends in biotechnology · doi:10.1016/j.tibtech.2021.03.005 · Cited by 24 · see citing works
Ren, L., Huang, D., Liu, H., Lin, N., Cai, P., Yu, X., Zhang, Y., Luo, N., Lin, H., Su, J., et al. (2024) · Oncology Letters · doi:10.3892/ol.2024.14285 · Cited by 27 · see citing works
Zhu, Y., Wang, X., Yue, L., Zuo, D., Sheng, J., Lan, S., Zhao, Z., Dong, S., Hu, S. S., Chen, X., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107186 · Cited by 26 · see citing works
Menegatti, S., López‐Cobo, S., Galy, A. S. D., Fuentealba, J. R., Silva, L. E., Perrin, L., Heurtebise-Chrétien, S., Pottez-Jouatte, V., Darbois, A., Burgdorf, N., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01282-8 · Cited by 28 · see citing works
Abken, H. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.165 · Cited by 26 · see citing works
Pooled Genome-Scale CRISPR Screens in Single Cells
Schraivogel, D., Steinmetz, L. M., & Parts, L. (2023) · Annual Review of Genetics · doi:10.1146/annurev-genet-072920-013842 · Cited by 26 · see citing works
Integration of Organoids With CRISPR Screens: A Narrative Review
Mukhare, R., Gandhi, K., Kadam, A., Raja, A., Singh, A., Madhav, M., Chaubal, R., Pandey, S., & Gupta, S. (2025) · Biology of the Cell · doi:10.1111/boc.70006 · Cited by 23 · see citing works
High-content CRISPR screening in tumor immunology
Holcomb, E. A., Pearson, A. N., Jungles, K. M., Tate, A., James, J. G., Jiang, L., Huber, A. K., & Green, M. D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1041451 · Cited by 24 · see citing works
Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies
Dobrin, A., Lindenbergh, P. L., Shi, Y., Perica, K., Xie, H., Jain, N., Chow, A., Wolchok, J. D., Merghoub, T., Sadelain, M., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00744-x · Cited by 23 · see citing works
Fix, S. M., Jazaeri, A. A., & Hwu, P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1083 · Cited by 24 · see citing works
Current Treatment Options for Renal Cell Carcinoma: Focus on Cell-Based Immunotherapy
Hwang, A., Mehra, V., Chhetri, J. B., Ali, S., Tran, M. G. B., & Roddie, C. (2024) · Cancers · doi:10.3390/cancers16061209 · Cited by 22 · see citing works
Interrogating immune cells and cancer with CRISPR-Cas9
Buquicchio, F. A., & Satpathy, A. T. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.03.003 · Cited by 21 · see citing works
CRISPR screening in hematology research: from bulk to single-cell level
Meyers, S., Demeyer, S., & Cools, J. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01495-5 · Cited by 23 · see citing works
Tang, L., Huang, Z., Mei, H., & Hu, Y. (2023) · Military Medical Research · doi:10.1186/s40779-023-00486-4 · Cited by 24 · see citing works
Miao, L., Zhang, J., Xu, W., Qian, Q., Zhang, G., Yuan, Q., Lv, Y., Zhang, H., Shen, C., & Wang, W. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2338984 · Cited by 22 · see citing works
Engineering CAR‐T Therapeutics for Enhanced Solid Tumor Targeting
Zhu, D., Kim, W., Lee, H., Bao, X., & Kim, P. (2025) · Advanced Materials · doi:10.1002/adma.202414882 · Cited by 21 · see citing works
B cell targeting in CAR T cell therapy: Side effect or driver of CAR T cell function?
Chen, G. M., Melenhorst, J. J., & Tan, K. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn3353 · Cited by 21 · see citing works
Mukherjee, P., Park, S. H., Pathak, N., Patino, C. A., Bao, G., & Espinosa, H. D. (2022) · ACS Nano · doi:10.1021/acsnano.2c05494 · Cited by 20 · see citing works
- Authors
- Roth, T. L., Li, P. J., Blaeschke, F., Nies, J. F., Apathy, R., Mowery, C., Yu, R., Nguyen, M. L. T., Lee, Y., Truong, A., Hiatt, J., Wu, D., Nguyen, D. N., Goodman, D., Bluestone, J. A., Ye, C. J., Roybal, K., Shifrut, E., & Marson, A.
- Affiliations
- University of California, San Francisco (US)
- Corresponding author
- Roth, Theodore L.
- Marson, Alexander
- ORCID
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 181
- Issue
- 3
- Pages
- 728-744.e21
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC7219528
- OpenAlex
- W3017040524
- Semantic Scholar
- fef922b8a02fcf158d7a3465ed812a49ef0538b1
- Cited by
- 186
- References
- 77
- Citations by year
- 2026: 11 · 2025: 23 · 2024: 25 · 2023: 29 · 2022: 45 · 2021: 32 · 2020: 19 · 2019: 1
- FWCI
- 10.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- T cell engineering, adoptive immunotherapy, barcoding, single-cell transcriptomics, cancer immunotherapy
- MeSH terms
- RNA, Guide, CRISPR-Cas Systems, Animals, Blood Cells, Genetic Engineering, Humans, Immunotherapy, T-Lymphocytes, Mice, SCID, Mice, Inbred NOD, Mice, Gene Knock-In Techniques, Single-Cell Analysis, Transcriptome, Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-05.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-05.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review